| Project/Area Number |
23591290
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Toneyama National Hospital |
|---|
Principal Investigator |
SAITO Toshio 独立行政法人国立病院機構刀根山病院(臨床研究部), その他部局等, 研究員 (60538776)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHIRA Yoshinobu 大阪大学医学(系), 研究科(研究院), 教授 (50185378)
FUJIMURA Harutoshi 国立病院機構, 刀根山病院, 臨床研究部長 (20263246)
MATSUMURA Tsuyoshi 国立病院機構, 刀根山病院 神経内科, 部長 (30549366)
SAKODA Saburo 国立病院機構, 刀根山病院, 院長 (00178625)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SOMA Toshihiro 兵庫医科大学, 血液内科学, 准教授 (40273619)
TAURA Akie 大阪南医療センター, 臨床研究部, 研究員 (80644533)
TADA Satoru 大阪大学, 微生物病研究所, 分子免疫制御分野 (70626530)
YAMADERA Misaki 国立病院機構, 刀根山病院 神経内科, 医員 (90649906)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | Duchenne型筋ジストロフィー / 微小循環障害 / 末梢血血管内皮前駆細胞 / ホスホジエステラーゼ5阻害剤 / 末梢血血管内皮前駆細胞: / ホスホジエステラーゼ５阻害剤 / ジストロフィン異常症 / CD34 / シルデナフィル / NIRS |
|---|
| Research Abstract |
In Duchenne muscular dystrophy (DMD), microcirculation abnormalities due to the vascular smooth muscle dysfunction influence the pathomechanism of the disease. The number of the peripheral blood circulation CD34-positive cell counts, which reflects microcirculation abnormalities, shows a higher tendency in low age group of DMD. However, the changes of number of peripheral blood CD34-positive cell counts showed no significant change in the phosphodiesterase 5A inhibitor administration for the purpose of improvement of DMD condition by affecting the microcirculation improvement. It is necessary to evaluate the number of peripheral blood CD34-positive cell counts whether it is useful as the DMD treatment marker.
|
